

Replies to reviewer's comments:

1. What is the full spell of FFX (Page 3, line 3)? **Reply: This has been clarified.**
2. Please add the citation of MPACT trial (Page 5, line 20)? **Reply: This has been done.**
3. Why didn't authors add a report (citation number 20) in Table 1? **Reply: Citation 20 was already included in Table 1.**
4. Would you please teach me the reasons of a sentence "only 20% of the real-world PDAC population would be eligible for treatment" (Page 6, line 22)? **Reply: This sentence has been removed as we, nevertheless, had to remove one of the auto-citations.**
5. A Swedish study was not involved Table 3 (Page 8, line 3-7)? **Reply: The Kordes paper is now referred to in Table 3.**
6. What is the full spell of OS2 (Page 9, line 23)? **Reply: We have clarified that OS2 means median OS counted from initiation of second-line chemotherapy.**
7. Would you please add the explanations of abbreviations (mOS, mPFS, GnP, FFX, p, L, etc...) in all tables? **Reply: We have added the explanations for all abbreviations in all tables.**
8. Can authors add information about the number of locally advanced or metastatic pancreatic cancer patients in tables? **Reply: This has been amended according to the suggestion.**
9. In table 1, albumin < 37, age < 65 are the conditions of worse survival. Would you please add the description in table 1? **Reply: This information has been added.**
10. Would you please add the citation numbers in all tables? **Reply: This has been added.**
11. In table 4, the 2L regimen of a report written by Nguyen 2017 was GnP (n = 30), Gem (n = 8), BSC (n = 22) **Reply: This might be a misunderstanding. We have doublechecked the reference and all figures now match.**
12. In a report written by Matsumoto et al 2020 (Table 5), the mOS of FFX was 6.9 months. On the other hand, the mOS of modified FFX was 12.8 months. Was there a significant difference between the mOS of FFX and the mOS of modified FFX? **Reply: The difference was not significant. We have added a sentence on this in last row page 10.**
13. In table 5, "1L rwegimen" was wrong. **Reply: Spelling has been corrected.**
14. Can you add the description about adverse events in all tables? If you can't do it, you can't help it. **Reply: Key toxicity data have now been added in the tables.**

Replies to science editor:

1 Scientific quality: The manuscript describes a review of the real world evidence on first and second line palliative chemotherapy in advanced pancreatic cancer. The topic is within the scope of the WJCO.

(1) Classification: Grade A;

(2) Summary of the Peer-Review Report: The authors described the detail of chemotherapy in advanced pancreatic cancer. This is a good review. However, the questions raised by the reviewer should be answered; and

(3) Format: There are 5 tables.

(4) References: A total of 63 references are cited, including 22 references published in the last 3 years;

(5) Self-cited references: There are 8 self-cited references. The self-referencing rates should be less than 10%. Please keep the reasonable self-citations that are closely related to the topic of the manuscript, and remove other improper self-citations. If the authors fail to address the critical issue of self-citation, the editing process of this manuscript will be terminated. **Reply: One self-citation has been removed, which means there are now 6 / 66 self-citations (i.e. <10%).**

(6) References recommend: The authors have the right to refuse to cite improper references recommended by peer reviewer(s), especially the references published by the peer reviewer(s) themselves. If the authors found the peer reviewer(s) request the authors to cite improper references published by themselves, please send the peer reviewer's ID number to the editorialoffice@wignet.com. The Editorial Office will close and remove the peer reviewer from the F6Publishing system immediately.

2 Language evaluation: Classification: Grade A.

3 Academic norms and rules: No academic misconduct was found in the Bing search.

4 Supplementary comments: This is an invited manuscript. The manuscript was supported by 3 grants. The topic has not previously been published in the WJCO.

5 Issues raised:

(1) The "Author Contributions" section is missing. Please provide the author contributions; **Reply: We have added a short Authors Contributions paragraph.**

(2) PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout; **Reply: We have added PMID and DOI and listed all authors for all references.**

(3) The authors did not provide the approved grant application form(s). Please upload the approved grant application form(s) or funding agency copy of any approval document(s); **Reply: We have now uploaded these documents.**

(4) The column should be minireviews.

6 Recommendation: Conditional acceptance.